Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Apellis Pharmaceuticals (APLS) EBIAT (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EBIAT data on record, last reported at -$59.0 million in Q4 2025.

  • For Q4 2025, EBIAT fell 62.16% year-over-year to -$59.0 million; the TTM value through Dec 2025 reached $22.4 million, up 111.31%, while the annual FY2025 figure was $22.4 million, 111.31% up from the prior year.
  • EBIAT reached -$59.0 million in Q4 2025 per APLS's latest filing, down from $215.7 million in the prior quarter.
  • Across five years, EBIAT topped out at $215.7 million in Q3 2025 and bottomed at -$219.2 million in Q2 2021.
  • Average EBIAT over 5 years is -$105.1 million, with a median of -$130.5 million recorded in 2022.
  • Peak YoY movement for EBIAT: plummeted 289.02% in 2021, then surged 475.52% in 2025.
  • A 5-year view of EBIAT shows it stood at -$147.9 million in 2021, then decreased by 12.21% to -$166.0 million in 2022, then soared by 46.64% to -$88.6 million in 2023, then skyrocketed by 58.96% to -$36.4 million in 2024, then plummeted by 62.16% to -$59.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$59.0 million in Q4 2025, $215.7 million in Q3 2025, and -$42.2 million in Q2 2025.